Enfuvirtide: Difference between revisions

Latest revision as of 03:30, 13 February 2025

Enfuvirtide[edit]

Enfuvirtide is an antiretroviral drug used in the treatment of HIV/AIDS. It is classified as a fusion inhibitor, which means it prevents the HIV virus from entering human cells. Enfuvirtide is marketed under the brand name Fuzeon.

Mechanism of Action[edit]

Enfuvirtide works by binding to the gp41 subunit of the HIV envelope glycoprotein. This binding prevents the conformational changes required for the fusion of the viral and cellular membranes, thereby inhibiting the entry of the virus into the host CD4+ T cells.

Administration[edit]

Enfuvirtide is administered via subcutaneous injection. It is typically used in combination with other antiretroviral agents in patients who have developed resistance to other treatments. The standard dosage involves twice-daily injections.

Side Effects[edit]

Common side effects of enfuvirtide include injection site reactions, such as pain, redness, and swelling. Other side effects may include insomnia, peripheral neuropathy, and eosinophilia.

Clinical Use[edit]

Enfuvirtide is primarily used in patients with multidrug-resistant HIV. It is often reserved for those who have not responded adequately to other antiretroviral therapies. Due to its mode of administration and cost, it is not typically used as a first-line treatment.

Development and Approval[edit]

Enfuvirtide was developed by Trimeris Inc. in collaboration with Roche. It was approved by the U.S. Food and Drug Administration (FDA) in 2003, making it the first fusion inhibitor available for clinical use.

Related pages[edit]

@@ Line 1: / Line 1: @@
-{{intro}}
+== Enfuvirtide ==
-Enfuvirtide is an [[HIV]] fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus ([[HIV]]).
-{{livtox}}
+[[File:Enfuvirtide.svg|thumb|right|Chemical structure of Enfuvirtide]]
-Enfuvirtide has not been associated with serum [[aminotransferase]] elevations during therapy or episodes of acute, clinically apparent [[liver injury]].
-{{moa}}
+'''Enfuvirtide''' is an [[antiretroviral drug]] used in the treatment of [[HIV/AIDS]]. It is classified as a [[fusion inhibitor]], which means it prevents the [[HIV]] virus from entering human cells. Enfuvirtide is marketed under the brand name '''Fuzeon'''.
-Enfuvirtide (en fue' vir tide) is relatively new antiretroviral drug that blocks the fusion of [[HIV]] to target cell, preventing viral entry and subsequent infection. Enfuvirtide is a 36 amino acid biomimetic peptide that resembles the [[HIV]] proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. Enfuvirtide has both in vitro and in vivo activity against [[HIV]], and several randomized controlled trials have shown that it leads to significant decline in [[HIV]] RNA levels and rises in peripheral [[CD4 T cell counts].
-{{fda}}
+== Mechanism of Action ==
-{{PAGENAME}} was approved for use in the United States in 2003, but it has had limited use, partially because it requires parenteral administration once or twice daily. Enfuvirtide is available in single use vials that contain 90 mg/mL after reconstitution under the brand name of Fuzeon. The recommended regimen for enfuvirtide is 90 mg subcutaneously twice daily in adults and 2 mg/kg in children ages 6 to 16. Enfuvirtide is recommended only in combination with other antiretroviral agents.
-{{se}}
+Enfuvirtide works by binding to the [[gp41]] subunit of the [[HIV envelope glycoprotein]]. This binding prevents the conformational changes required for the fusion of the viral and cellular membranes, thereby inhibiting the entry of the virus into the host [[CD4+ T cells]].
-The only common side effects specifically linked to enfuvirtide have been injection site reactions (which can be troublesome) and eosinophilia. Regimens that include enfuvirtide have the potential to cause immune reconstitution syndrome, pneumonitis and severe hypersensivity reactions.
-{{antiviral agents}}
+== Administration ==
-{{coststubd}}
+Enfuvirtide is administered via [[subcutaneous injection]]. It is typically used in combination with other antiretroviral agents in patients who have developed resistance to other treatments. The standard dosage involves twice-daily injections.
+== Side Effects ==
+Common side effects of enfuvirtide include injection site reactions, such as pain, redness, and swelling. Other side effects may include [[insomnia]], [[peripheral neuropathy]], and [[eosinophilia]].
+== Clinical Use ==
+Enfuvirtide is primarily used in patients with [[multidrug-resistant HIV]]. It is often reserved for those who have not responded adequately to other antiretroviral therapies. Due to its mode of administration and cost, it is not typically used as a first-line treatment.
+== Development and Approval ==
+Enfuvirtide was developed by [[Trimeris Inc.]] in collaboration with [[Roche]]. It was approved by the [[U.S. Food and Drug Administration]] (FDA) in 2003, making it the first fusion inhibitor available for clinical use.
+== Related pages ==
+* [[HIV/AIDS]]
+* [[Antiretroviral drug]]
+* [[Fusion inhibitor]]
+* [[CD4+ T cell]]
+[[Category:Antiretroviral drugs]]
+[[Category:HIV/AIDS treatment]]